Licraside

CAS No. 29913-71-1

Licraside( Licuraside )

Catalog No. M26739 CAS No. 29913-71-1

Licraside is a tyrosinase inhibitor with an IC50 of 0.072 mM for monophenolase and can be used in studies about antibrowning and depigmenting agents.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 158 In Stock
10MG 259 In Stock
25MG 419 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Licraside
  • Note
    Research use only, not for human use.
  • Brief Description
    Licraside is a tyrosinase inhibitor with an IC50 of 0.072 mM for monophenolase and can be used in studies about antibrowning and depigmenting agents.
  • Description
    Licraside is a tyrosinase inhibitor with an IC50 of 0.072 mM for monophenolase and can be used in studies about antibrowning and depigmenting agents.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Licuraside
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Tyrosinase
  • Recptor
    MAO-B
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    29913-71-1
  • Formula Weight
    550.513
  • Molecular Formula
    C26H30O13
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (181.65 mM)
  • SMILES
    [H][C@]1(O[C@@H]2OC[C@](O)(CO)[C@H]2O)[C@H](Oc2ccc(C(=O)\C=C\c3ccc(O)cc3)c(O)c2)O[C@H](CO)[C@@H](O)[C@@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Tzvetkov NT, et al. Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. J Med Chem. 2014 Aug 14;57(15):6679-703.
molnova catalog
related products
  • KN-93

    KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase.

  • NDI-034858

    NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases caused by aberrant expression of IL12 and IL23.

  • Sodium etidronate

    A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.